Business, energy, technology, markets and global industry news from Business News Today

Tolmar Inc.

PharmaDeviceNews Tolmar Inc.
Representative image of prostate cancer genomics research, relevant to our feature on how BRCA mutations are emerging as therapeutic drivers and reshaping precision oncology in prostate cancer.
Features & Analysis

Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies

The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in

Read More
Representative image of PARP inhibitor research and formulation. Relevant to our feature on how drugs like Rubraca, Lynparza, and others are reshaping prostate cancer treatment after setbacks in ovarian cancer.
Features & Analysis

Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?

The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025

Read More
Pharma & Biotech

Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies

Rubraca’s FDA approval before chemo in BRCA-mutated prostate cancer could reshape precision treatment. See what this changes for mCRPC strategy.

Read More
Representative image showing a prostate cancer research and testing environment, aligned with our coverage of Rubraca’s FDA approval and its Phase 3 TRITON3 trial results in BRCA-mutated metastatic castration-resistant prostate cancer.
Pharma & Biotech

Tolmar secures FDA nod for pre-chemo Rubraca use in BRCA-mutated prostate cancer

Tolmar Inc. has received expanded approval from the U.S. Food and Drug Administration for Rubraca (rucaparib), enabling its use before chemotherapy in patients with metastatic castration-resistant prostate cancer who carry BRCA mutations. The decision was based on results from the TRITON3 Phase 3 trial, which showed Rubraca to be the first and only PARP inhibitor

Read More